Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Sartorius AG (DE:SRT3)
XETRA:SRT3
Sartorius (SRT3) Stock Price & Analysis
16 Followers
SRT3 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€214.87 - €382.93
Previous Close€271.6
Volume92.70K
Average Volume (3M)95.85K
Market Cap
€16.69B
Enterprise Value€19.70B
Total Cash (Recent Filing)€196.80M
Total Debt (Recent Filing)€2.54B
Price to Earnings (P/E)125.0
Beta1.79
Next Earnings
Jul 19, 2024EPS Estimate
€1.13Last Dividend Ex-Date
Apr 02, 2024Dividend Yield0.52%
Share Statistics
EPS (TTM)2.17
Shares OutstandingN/A
10 Day Avg. Volume129,419
30 Day Avg. Volume95,847
Standard Deviation0.11
R-Squared0.03
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€360.78Price Target Upside32.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
Sartorius News
PremiumPre-Earnings
Is 0NIR a Buy, Before Earnings?
Bulls Say, Bears Say
Bulls Say
Financial HealthThe company's EBITDA margin reflects cost control and mix, indicating a more robust bottom-line than expected.
Future Growth ProspectsThe company communicated new mid-term targets for 2028 aiming for average annual growth in group sales of a lower double-digit percent and an adj. EBITDA margin of around 34%.
Market ExpansionOrder intake in North America showed a dramatic improvement, which is a positive sign for the company's recovery.
Bears Say
Corporate FinanceThe company's mention of potential equity measures, which had been previously ruled out, has taken investors by surprise.
EarningsSRT reported results that fell significantly short of both consensus and SFe forecasted revenue figures.
Market DemandIn China, there is a continued softness in demand, as evidenced by a 4.8% drop in organic order intake.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00%
Insiders
19.72% Mutual Funds
7.21% Other Institutional Investors
73.07% Public Companies and
Individual Investors
SRT3 FAQ
What was Sartorius AG’s price range in the past 12 months?
Sartorius AG lowest stock price was €214.87 and its highest was €382.93 in the past 12 months.
What is Sartorius AG’s market cap?
Currently, no data Available
When is Sartorius AG’s upcoming earnings report date?
Sartorius AG’s upcoming earnings report date is Jul 19, 2024 which is in 84 days.
How were Sartorius AG’s earnings last quarter?
Sartorius AG released its earnings results on Apr 18, 2024. The company reported €1.02 earnings per share for the quarter, missing the consensus estimate of €1.102 by -€0.082.
Is Sartorius AG overvalued?
According to Wall Street analysts Sartorius AG’s price is currently Undervalued.
Does Sartorius AG pay dividends?
Sartorius AG pays a Annually dividend of €0.74 which represents an annual dividend yield of 0.52%. See more information on Sartorius AG dividends here
What is Sartorius AG’s EPS estimate?
Sartorius AG’s EPS estimate is €1.13.
How many shares outstanding does Sartorius AG have?
Sartorius AG has 37,440,000 shares outstanding.
What happened to Sartorius AG’s price movement after its last earnings report?
Sartorius AG reported an EPS of €1.02 in its last earnings report, missing expectations of €1.102. Following the earnings report the stock price went down -15.408%.
Which hedge fund is a major shareholder of Sartorius AG?
Currently, no hedge funds are holding shares in DE:SRT3
---
Sartorius Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-15.67%
12-Months-Change
Fundamentals
Return on Equity
10.11%
Trailing 12-Months
Asset Growth
39.82%
Trailing 12-Months
Company Description
Sartorius AG
Sartorius AG is the leading provider of biopharmaceutical fermentation and fluid management. In 2019, the bioprocess division contributed 77% to total revenue and the lab division the remaining 23%. The bioprocess division is traded as a separate company, Sartorius Stedim Biotech. Sartorius AG has a 74% ownership of this subsidiary with 85% voting control. In addition to biomanufacturing equipment and consumables, Sartorius offers a wide range of products for general lab use, such as scales, pipettes, and filtration equipment. The business is geographically diverse, with revenue across Europe, the Middle East, and Africa (38% of 2019 sales), the Americas (37%), and Asia-Pacific (25%). Sartorius employs over 9,000 people and has operations in more than 30 countries.
---
SRT3 Stock 12 Months Forecast
Average Price Target
€360.78
▲(32.44% Upside)
Technical Analysis
Best Analysts Covering SRT3
1 Year
1 Year Success Rate
5/13 ratings generated profit
1 Year Average Return
-0.75%
reiterated a buy rating 9 days ago
Copying Odysseas Manesiotis's trades and holding each position for 1 Year would result in 38.46% of your transactions generating a profit, with an average return of -0.75% per trade.
---